+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess how effective and safe RO7837195 is for these patients. The study is sponsored by Genentech, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants will undergo a screening period lasting up to 5 weeks to determine eligibility. The main treatment includes a 12-week placebo-controlled induction phase, after which all participants receive RO7837195 during a 40-week active treatment extension. RO7837195 is given according to predefined dose regimens, and the study includes multiple experimental groups receiving different doses, as well as a group initially receiving placebo followed by RO7837195. Throughout the study, participants will have regular assessments to measure clinical remission at week 12, clinical response, endoscopic improvement, and safety through monitoring adverse events and blood levels of the drug. The studys total duration includes the screening, treatment phases, and a safety follow-up after the last dose, with outcome measures tracked up to week 65. Researchers will also monitor for the development of antibodies against RO7837195 to further understand treatment effects and safety.

Age: 18Years +All GendersPhase 2
111 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.

Age: 18Years - 80YearsAll GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
R

Actively Recruiting

Researchers are evaluating lumateperone as an additional treatment for adults aged 18 to 65 years with major depressive disorder MDD who have not responded adequately to current antidepressant treatments. This phase 3, multicenter study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy and safety of lumateperone in this population. The study includes patients with moderate to severe depression diagnosed according to DSM-5 criteria, including those with psychotic features. Participants will be randomly assigned to receive either lumateperone 42 mg capsules or matching placebo capsules once daily for six weeks during the double-blind treatment period. The study consists of three distinct periods an initial screening lasting up to two weeks to determine eligibility, the six-week treatment phase with daily medication, and a one-week safety follow-up after the last dose to monitor any adverse effects. During the study, participants will undergo assessments including depression rating scales such as the Montgomery-Asberg Depression Rating Scale MADRS and Clinical Global Impression Scale-Severity. Safety evaluations will be conducted throughout, including a follow-up visit about one week after treatment ends. The total participation time may last up to nine weeks, encompassing screening, treatment, and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
69 locations